Wednesday, February 4, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Earnings

Figma Faces Critical Test as Earnings and Share Lockup Converge

Dieter Jaworski by Dieter Jaworski
November 5, 2025
in Earnings, IPOs, Nasdaq, Tech & Software, Trading & Momentum
0
Figma Stock
0
SHARES
111
VIEWS
Share on FacebookShare on Twitter

The atmosphere surrounding Figma is reaching a fever pitch as the design software company approaches two potentially market-moving events. After US markets close this evening, the firm will release its quarterly results, with investors anticipating a decisive directional move for the shares. Compounding the tension, a significant lockup period expires just forty-eight hours later, creating what could become a perfect storm for a stock that has already declined 60% since its July IPO.

Earnings Scrutiny Intensifies

Market attention is firmly fixed on tonight’s financial disclosure. Research analysts project revenue of approximately $264 million with earnings of 5 cents per share. The growth trajectory represents perhaps the most critical metric under examination. While last quarter saw revenue expand by 41%, this pace marked a noticeable deceleration compared to previous periods. The central question facing investors is whether Figma can reignite its expansion narrative or if further disappointment lies ahead.

Analyst Perspectives and Market Realities

Despite the substantial price depreciation, financial experts maintain cautious optimism. The average price target sits around $70, suggesting significant potential upside from current trading levels. However, the present share price of approximately $40 reflects growing investor apprehension. Particular concern stems from slowing momentum among enterprise clients, with the Net Dollar Retention Rate declining to 129%, raising questions about the sustainability of future growth.

Should investors sell immediately? Or is it worth buying Figma?

Lockup Expiration Looms

Adding another layer of complexity, Friday’s expiration of IPO trading restrictions could introduce additional downward pressure. This milestone will enable early investors and company insiders to sell their holdings for the first time. Historical patterns indicate that such lockup terminations frequently precipitate increased volatility and selling activity—a dangerous combination for shares already trending downward.

Tonight’s earnings release will prove pivotal in determining whether Figma can reassure skeptical market participants or if the downward trajectory will continue. With the dual pressures of quarterly results and impending share unlock, the coming days will likely prove decisive for the embattled stock’s near-term direction.

Ad

Figma Stock: Buy or Sell?! New Figma Analysis from February 4 delivers the answer:

The latest Figma figures speak for themselves: Urgent action needed for Figma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 4.

Figma: Buy or sell? Read more here...

Tags: Figma
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

National Healthcare Stock
Earnings

National Healthcare’s Financial Report: A Crucial Test Approaches

February 4, 2026
XRP Stock
Banking & Insurance

XRP’s Dual Milestone: Regulatory Green Light Meets Core Protocol Upgrade

February 4, 2026
QuantumScape Stock
Analysis

QuantumScape Investors Await Critical Milestones After Share Price Decline

February 4, 2026
Next Post
Salesforce Stock

Salesforce Shares Face Investor Skepticism Despite Strong Earnings

Boston Omaha Stock

Boston Omaha Shares Face Mounting Pressure as Technical Outlook Worsens

DMC Global Stock

DMC Global Shares Face Pressure Amid Mixed Quarterly Results

Recommended

Caleres Stock

Caleres Prepares for Pivotal Earnings Release Amid Strategic Shifts

6 months ago
Opera Stock

Opera Shares Tumble Despite Record Financial Performance

3 months ago
MA stock news

National Bank of Canada FI Sheds Majority Stake in Burlington Stores, Inc. Sparks Speculation and Uncertainty in Retail Sector

3 years ago
PayPal Stock

PayPal Shares Face Mounting Headwinds as Core Business Cools

3 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Coinbase Faces Mounting Pressure from Legal and Reputational Challenges

Terawulf Expands Infrastructure Portfolio with Major Site Acquisitions

QuantumScape Investors Await Critical Milestones After Share Price Decline

Chevron Shares Maintain Momentum Amid Record Production and Dividend Growth

UBS Shares Slide Despite Strong Earnings: A Closer Look at Investor Concerns

Can Midnight’s Privacy Push Revive Cardano’s Stagnant Valuation?

Trending

Arcus Biosciences Stock
Analysis

Arcus Biosciences Pivots Pipeline Strategy Following Clinical Setback

by Andreas Sommer
February 4, 2026
0

Biotechnology firm Arcus Biosciences is executing a strategic overhaul of its clinical development portfolio after a significant...

National Healthcare Stock

National Healthcare’s Financial Report: A Crucial Test Approaches

February 4, 2026
XRP Stock

XRP’s Dual Milestone: Regulatory Green Light Meets Core Protocol Upgrade

February 4, 2026
Coinbase Stock

Coinbase Faces Mounting Pressure from Legal and Reputational Challenges

February 4, 2026
Terawulf Stock

Terawulf Expands Infrastructure Portfolio with Major Site Acquisitions

February 4, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Arcus Biosciences Pivots Pipeline Strategy Following Clinical Setback
  • National Healthcare’s Financial Report: A Crucial Test Approaches
  • XRP’s Dual Milestone: Regulatory Green Light Meets Core Protocol Upgrade

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com